Summary by Futu AI
CVS Health Corporation, a leading health solutions company, has announced the issuance of a series of senior notes under its Prospectus Supplement filed pursuant to Rule 424(b)(2) with the SEC. The offering includes $5 billion in aggregate principal amount of senior notes with varying interest rates and maturities ranging from 2029 to 2054. The notes are unsecured and will pay interest semi-annually, with the first payment commencing on December 1, 2024. The company plans to use the net proceeds for general corporate purposes, which may include working capital, satisfying statutory capital requirements, capital expenditures, and repayment of existing indebtedness. The senior notes are expected to be delivered on or about May 9, 2024, through book-entry form only via The Depository Trust Company and its participants, including Euroclear Bank SA/NV and Clearstream Banking S.A. The underwriting syndicate for the offering is led by BofA Securities, Barclays, Goldman Sachs & Co. LLC, J.P. Morgan, and Wells Fargo Securities, among others. The date of the prospectus supplement is May 7, 2024.